RCN Pareto Strategic Allocation ETF (NYSEARCA:PRTO) Stock Short Interest Declines 38.5%

RCN Pareto Strategic Allocation ETF (NYSEARCA:PRTO) was the target of a large drop in short interest during the month of October. As of October 15th, there was short interest totaling 425 shares, a drop of 38.5% from the September 30th total of 691 shares. Based on an average daily volume of 257 shares, the days-to-cover ratio is currently 1.7 days. Approximately 0.1% of the shares of the company are sold short.

RCN Pareto Strategic Allocation ETF Price Performance

PRTO stock traded up $0.18 during midday trading on Tuesday, reaching $27.09. 134 shares of the company were exchanged. RCN Pareto Strategic Allocation ETF has a one year low of $24.68 and a one year high of $28.58. The firm has a market capitalization of $17.34 million, a price-to-earnings ratio of -28.22 and a beta of 1.04. The stock’s 50-day simple moving average is $27.52.

Proteon Therapeutics was a biopharmaceutical company focused on developing treatments for patients with kidney and vascular diseases. The company’s research and development efforts centered on therapies designed to address severe and life-threatening conditions, particularly those related to renal disease and vascular access for hemodialysis patients.

One of Proteon Therapeutics’ best-known product candidates was vonapanitase, an investigational enzyme developed to improve vascular access outcomes in patients with end-stage renal disease who require hemodialysis.